Mitochondrial TSPO as a target for metabolic syndrome interventions

Authors

  • Lukasz Kurach Independent Laboratory of Behavioral Studies, Medical University of Lublin, Poland Author

DOI:

https://doi.org/10.12923/cipms-2025-0023

Keywords:

TSPO, diabetes, obesity, cholesterol, metabolic syndrome

Abstract

The 18 kDa translocator protein (TSPO) is a protein located in the outer mitochondrial membrane that plays a crucial role in mitochondrial transport, maintaining cellular homeostasis, and ensuring normal cell function. TSPO has beneficial effects in regulating various pathophysiological processes, including the inflammatory response, oxidative stress, steroid synthesis and microglial function. The use of TSPO ligands in different experimental settings has led to their translation to clinical trials for treating neurological and psychiatric diseases. Since TSPO drug ligands influence numerous local processes, such as adipokine secretion, glucose metabolism and adipogenesis, TSPO may represent a promising therapeutic target with potential application for metabolic syndrome. From a clinical perspective, targeting mitochondrial metabolism to modulate energy homeostasis is a promising strategy for developing new antidiabetic or anti-obesity drugs. This review aims to summarize current knowledge of TSPO and its potential as a therapeutic target in metabolic syndrome.

References

1. Dobrowolski P, Prejbisz A, Kuryłowicz A, Baska A, Burchardt P, Chlebus K, et al. Metabolic Syndrome – a new definition and management guidelines. Arterial Hypertension. 2022;26:99-121.

2. International Diabetes Federation IDF Diabetes Atlas. Brussels, Belgium; 2021.

3. Deng Y, Yang Q, Hao C, Wang HH, Ma T, Chen X, et al. Combined lifestyle factors and metabolic syndrome risk: A systematic review and meta-analysis. Int J Obes. 2025;49:226-36.

4. Jung UJ, Choi M-S. Obesity and its metabolic complications: The role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia, and nonalcoholic fatty liver disease. Int J Mol Sci. 2014;15:6184-223.

5. Bakkar N-MZ, AlZaim I, El-Yazbi AF. Depot-specific adipose tissue modulation by SGLT2 inhibitors and GLP1 agonists mediates their cardioprotective effects in metabolic disease. Clin Sci. 2022;136:1631-51.

6. Guru B, Tamrakar AK, Manjula SN, Prashantha Kumar BR. Novel dual PPARα/γ agonists protect against liver steatosis and improve insulin sensitivity while avoiding side effects. Eur J Pharmacol. 2022;935:175322.

7. Luukkonen PK. Hidden metabolic effects of Acetyl-CoA carboxylase inhibition. J Hepatol. 2025;82:544-5.

8. Lillich FF, Imig JD, Proschak E. Multi-target approaches in metabolic syndrome. Front Pharmacol. 2021;11:554961.

9. Braestrup C, Squires RF. Specific benzodiazepine receptors in rat brain characterized by high-affinity (3H)diazepam binding. Proc Natl Acad Sci U.S.A. 1977;74:3805-9.

10. Fan J, Campioli E, Midzak A, Culty M, Papadopoulos V. Conditional steroidogenic cell-targeted deletion of TSPO unveils a crucial role in viability and hormone-dependent steroid formation. Proc Natl Acad Sci U.S.A. 2015;112:7261-6.

11. Selvaraj V, Stocco DM, Tu LN. Minireview: Translocator Protein (TSPO) and Steroidogenesis: A reappraisal. Mol Endocrinol. 2015;29:490-501.

12. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapère J-J, Lindemann P, et al. Translocator protein (18kDa): New nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci. 2006;27:402-9.

13. Salerno S, Viviano M, Baglini E, Poggetti V, Giorgini D, Castagnoli J, et al. TSPO radioligands for neuroinflammation: An overview. Molecules. 2024;29:4212.

14. Ravikumar B, Crawford D, Dellovade T, Savinainen A, Graham D, Liere P, et al. Differential efficacy of the TSPO ligands etifoxine and XBD-173 in Two rodent models of multiple sclerosis. Neuropharmacology. 2016;108:229-37.

15. Rupprecht R, Rammes G, Eser D, Baghai TC, Schüle C, Troxler T, et al. Translocator protein (18 kD) as target for anxiolytics without benzodiazepine-like side effects. Science. 2009;325: 490-3.

16. Nguyen N, Fakra E, Pradel V, Jouve E, Alquier C, Le Guern ME, et al. Efficacy of etifoxine compared to lorazepam monotherapy in the treatment of patients with adjustment disorders with anxiety: A double‐blind controlled study in general practice. Hum Psychopharmacol. 2006;21:139-49.

17. Ugale RR, Sharma AN, Kokare DM, Hirani K, Subhedar NK, Chopde CT. Neurosteroid allopregnanolone mediates anxiolytic effect of etifoxine in rats. Brain Res. 2007;1184:193-201.

18. Doorduin J, Klein HC, Dierckx RA, James M. Kassiou M, De Vries EFJ. [11C]-DPA-713 and [18F]-DPA-714 as New PET tracers for TSPO: A comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Mol Imaging Biol. 2009;11:386-98.

19. Fan J, Campioli E, Papadopoulos V. Nr5a1-Cre-Mediated TSPO conditional knockout mice with low growth rate and prediabetes symptoms – a mouse model of stress diabetes. Biochim Biophys Acta Mol Basis Dis. 2019;1865:56-62.

20. Morrissey NA, Beall C, Ellacott KLJ. Absence of the mitochondrial translocator protein 18 kDa in mice does not affect body weight or food intake responses to altered energy availability. J Neuroendocrinol. 2021;33:13027.

21. Li J, Papadopoulos V. Translocator protein (18kDa) as a Pharmacological target in adipocytes to regulate glucose homeostasis. Biochem Pharmacol. 2015;97:99-110.

22. Farhan F, Raghupathy RK, Baran MR, Wong A, Biswas L, Jiang H-R, et al. Dysregulation of lipid metabolism in the liver of TSPO knockout mice. Biochim Biophys Acta Mol Cell Biol Lipids. 2025;1870:159566.

23. Li Y, Chen L, Li L, Sottas C, Petrillo SK, Lazaris A, et al. Cholesterol-binding translocator protein TSPO regulates steatosis and bile acid synthesis in nonalcoholic fatty liver disease. iScience. 2021;24:102457.

24. Gut P, Baeza-Raja B, Andersson O, Hasenkamp L, Hsiao J, Hesselson D, et al. Whole-organism screening for gluconeogenesis identifies activators of fasting metabolism. Nat Chem Biol. 2013;9:97-104.

25. Thompson MM, Manning HC, Ellacott KLJ. Translocator protein 18 kDa (TSPO) is regulated in white and brown adipose tissue by obesity. PLoS One. 2013;8:79980.

26. Kim S, Kim N, Park S, Jeon Y, Lee J, Yoo S-J, et al. Tanycytic TSPO inhibition induces lipophagy to regulate lipid metabolism and improve energy balance. Autophagy. 2020;16:1200-20.

27. Qiu Z-K, He J-L, Liu X, Zhang G-H, Zeng J, Nie H, et al. Antidepressant-like activity of AC-5216, a ligand for 18KDa translocator protein (TSPO), in an animal model of diabetes mellitus. Sci Rep. 2016;6:37345.

28. Giatti S, Pesaresi M, Cavaletti G, Bianchi R, Carozzi V, Lombardi R, et al. Neuroprotective effects of a ligand of translocator protein-18kDa (Ro5-4864) in experimental diabetic neuropathy. Neuroscience. 2009;164:520-9.

29. Mitro N, Cermenati G, Giatti S, Abbiati F, Pesaresi M, Calabrese D, et al. LXR and TSPO as new therapeutic targets to increase the levels of neuroactive steroids in the central nervous system of diabetic animals. Neurochem Int. 2012;60:616-21.

Downloads

Published

2025-08-12

How to Cite

Kurach, L. (2025). Mitochondrial TSPO as a target for metabolic syndrome interventions. Current Issues in Pharmacy and Medical Sciences, 38(3 (AOP). https://doi.org/10.12923/cipms-2025-0023